Fullgoal Fund Management Boosts Stake in Biocytogen With HK$3.2 Million Share Purchase

Deep News

Sep 07

Hong Kong stock exchange filings reveal that on September 2, Fullgoal Fund Management Co., Ltd. increased its holdings in Biocytogen Pharmaceuticals (Beijing) Co.,Ltd. (02315) by 50,000 shares, at a price of HK$64.377 per share, totaling approximately HK$3.2189 million.

Following this transaction, Fullgoal's latest shareholding count stands at roughly 9.9706 million shares, representing 9% of the company's total issued shares.

This move underscores the fund manager's continued confidence in the biopharmaceutical firm's growth prospects, with the purchase price reflecting a premium to recent trading levels.

The acquisition aligns with broader trends of institutional investors increasing their exposure to innovative drug developers in the region, as Biocytogen advances its pipeline of antibody therapies and research collaborations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/news/1143754716"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1143754716\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1143754716?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-07 08:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143754716","market":"sh","top_or_hot":-1,"title":"Fullgoal Fund Management Boosts Stake in Biocytogen With HK$3.2 Million Share Purchase","media":"Deep News","content":"<p>Hong Kong stock exchange filings reveal that on September 2, <b>Fullgoal Fund Management Co., Ltd.</b> increased its holdings in <b>Biocytogen Pharmaceuticals (Beijing) Co.,Ltd.</b> (02315) by 50,000 shares, at a price of HK$64.377 per share, totaling approximately HK$3.2189 million.<br><br>Following this transaction, Fullgoal's latest shareholding count stands at roughly 9.9706 million shares, representing 9% of the company's total issued shares.<br><br>This move underscores the fund manager's continued confidence in the biopharmaceutical firm's growth prospects, with the purchase price reflecting a premium to recent trading levels.<br><br>The acquisition aligns with broader trends of institutional investors increasing their exposure to innovative drug developers in the region, as <b>Biocytogen</b> advances its pipeline of antibody therapies and research collaborations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fullgoal Fund Management Boosts Stake in Biocytogen With HK$3.2 Million Share Purchase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFullgoal Fund Management Boosts Stake in Biocytogen With HK$3.2 Million Share Purchase\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-09-07 08:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong stock exchange filings reveal that on September 2, <b>Fullgoal Fund Management Co., Ltd.</b> increased its holdings in <b>Biocytogen Pharmaceuticals (Beijing) Co.,Ltd.</b> (02315) by 50,000 shares, at a price of HK$64.377 per share, totaling approximately HK$3.2189 million.<br><br>Following this transaction, Fullgoal's latest shareholding count stands at roughly 9.9706 million shares, representing 9% of the company's total issued shares.<br><br>This move underscores the fund manager's continued confidence in the biopharmaceutical firm's growth prospects, with the purchase price reflecting a premium to recent trading levels.<br><br>The acquisition aligns with broader trends of institutional investors increasing their exposure to innovative drug developers in the region, as <b>Biocytogen</b> advances its pipeline of antibody therapies and research collaborations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0216","symbol_name":"研究试验","start_time":0,"source_url":"","article_id":"1143754716","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143754716","pubTimestamp":1788740419,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Hong Kong stock exchange filings reveal that on September 2, Fullgoal Fund Management Co., Ltd. increased its holdings in Biocytogen Pharmaceuticals (Beijing) Co.,Ltd. (02315) by 50,000 shares, at a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688796":"百奥赛图","BK0216":"研究试验","EWH":"香港ETF-iShares MSCI"},"translate_title":"Fullgoal Fund Management以320万港元增持Biocytogen股份","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688796":1,"EWH":1},"content_text":"Hong Kong stock exchange filings reveal that on September 2, Fullgoal Fund Management Co., Ltd. increased its holdings in Biocytogen Pharmaceuticals (Beijing) Co.,Ltd. (02315) by 50,000 shares, at a price of HK$64.377 per share, totaling approximately HK$3.2189 million.Following this transaction, Fullgoal's latest shareholding count stands at roughly 9.9706 million shares, representing 9% of the company's total issued shares.This move underscores the fund manager's continued confidence in the biopharmaceutical firm's growth prospects, with the purchase price reflecting a premium to recent trading levels.The acquisition aligns with broader trends of institutional investors increasing their exposure to innovative drug developers in the region, as Biocytogen advances its pipeline of antibody therapies and research collaborations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}